Gleneagle Gold Ltd (ASX:GLN) continues to advance towards re-listing on the ASX as a medical cannabis company.
The company has now received a notice of initial substantial holder from Gemelli Nominees Pty Ltd, which holds 33.3 million shares, or around 5.5%.
Gleneagle is in the final steps of the reverse takeover of Zelda Therapeutics, a California-based biotechnology company.
Zelda is a biotechnology company that was spun out of a successful US-based medicinal cannabis group - Aunt Zelda’s - that has treated hundreds of patients in California.
The company will host its general meeting on the 25th July 2016 in Perth, where shareholders will vote on the significant change to the nature and scale of its activities.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.